Setmelanotide reduced BMI compared with placebo after 52 weeks of treatment in people with acquired hypothalamic obesity.
Why this rating
A direct, placebo-controlled phase 3 trial supports the outcome for this diagnosis. The study was sponsor funded, and the paper and FDA label describe different analysis populations. Neither supports generalizing to other causes of obesity.
GRADE downgrade factors applied
- Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
Supporting studies
- Setmelanotide for the Treatment of Acquired Hypothalamic ObesityRandomized Controlled TrialNew England Journal of Medicine2026n=120
A 52-week randomized trial found a greater reduction in BMI with setmelanotide than placebo in participants with acquired hypothalamic obesity. The journal report and current FDA label describe different analysis populations, so figures from them should retain their own source and denominator.